The effect of hydroxcarbamide therapy on survival of children with sickle cell disease

British Journal of Haematology

Volumn 161, Issue 6, 2013, Pages 852-860

  Lopes de Castro Lobo, Clarisse ^a   Pinto, Jorge F C ^a,b   Nascimento, Emilia M ^a,c   Moura, Patricia G ^a   Cardoso, Gilberto P ^d   Hankins, Jane S ^e  

^a Instituto de Hematologia 'Arthur de Siqueira Cavalcanti' HEMORIO   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Hydroxycarbamide; Immunizations; Mortality; Paediatric; Sickle cell disease

Indexed keywords

FOLIC ACID; HYDROXYUREA; PENICILLIN DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MORTALITY; NEUTROPENIA; NEUTROPHIL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETICULOCYTE; RETICULOCYTOPENIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA; SURVIVAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HEMOGLOBIN, SICKLE; HUMANS; HYDROXYUREA; MALE; TREATMENT OUTCOME;

EID: 84878516824     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12323     Document Type: Article

References (40)

1. Adamkiewicz, T.V., Silk, B.J., Howgate, J., Baughman, W., Strayhorn, G., Sullivan, K. & Farley, M.M. (2008) Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics, 121, 562-569.
2. Adewuyi, J.O. (1988) Morbidity of sickle cell disease in early childhood. Journal of Tropical Pediatrics, 34, 93.
3. Brousse, V., Elie, C., Benkerrou, M., Odievre, M.H., Lesprit, E., Bernaudin, F., Grimaud, M., Guitton, C., Quinet, B., Dangiolo, S. & de Montelambert, M. (2012) Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. British Journal of Haematology, 156, 643-648.
4. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. New England Journal of Medicine, 332, 1317-1322.
5. Darbari, D.S., Kple-Faget, P., Kwagyan, J., Rana, S., Gordeuk, V.R. & Castro, O. (2006) Circumstances of death in adult sickle cell disease patients. American Journal of Hematology, 81, 858-863.
6. Fernandes, A.P., Januario, J.N., Cangussu, C.B., Macedo, D.L. & Viana, M.B. (2010) Mortality of children with sickle cell disease: a population study. Journal of Pediatr (Rio J), 86, 279-284.
7. Gaston, M.H., Verter, J.I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., Zarkowsky, H., Vichinsky, E., Iyer, R., Lobel, J.S., Diamond, S., Holbrook, C.T., Gill, F.M., Ritchey, K. & Falletta, J.M. for the Prophylactic Penicillin Study Group. (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. New England Journal of Medicine, 314, 1593-1599.
8. Hardie, R., King, L., Fraser, R. & Reid, M. (2009) Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening. Annals of Tropical Paediatrics, 29, 197-202.
9. Hassell, K.L. (2010) Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine, 38, S512-S521.
10. Haynes, J. Jr, Obiako, B., Hester, R.B., Baliga, B.S. & Stevens, T. (2008) Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. American Journal of Physiology. Heart and Circulatory Physiology, 294, H379-H385.
11. Kalbfleisch, J. (1985) Probability and Statistical Inference: Statistical Inference, 2nd edn. Springer-Verlag, New York.
12. Khayat, A.S., Antunes, L.M., Guimaraes, A.C., Bahia, M.O., Lemos, J.A., Cabral, I.R., Lima, P.D., Amorim, M.I., Cardoso, P.C., Smith, M.A., Santos, R.A. & Burbano, R.R. (2006) Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea. Clinical and Experimental Medicine, 6, 33-37.
13. Lanzkron, S., Strouse, J.J., Wilson, R., Beach, M.C., Haywood, C., Park, H., Witkop, C., Bass, E.B. & Segal, J.B. (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Annals of Internal Medicine, 148, 939-955.
14. Lebensburger, J.D., Howard, T., Hu, Y., Pestina, T.I., Gao, G., Johnson, M., Zakharenko, S.S., Ware, R.E., Tuomanen, E.I., Persons, D.A. & Rosch, J.W. (2012) Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood, 119, 1915-1921.
15. Leikin, S.L., Gallagher, D., Kinney, T.R., Sloane, D., Klug, P. & Rida, W. (1989) Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics, 84, 500-508.
16. Lobo, C., Bueno, L.M., Moura, P., Castilho, S., Carvalho, S.M.F. & Ogeda, L.L. (2003) Triagem neonatal para hemoglobinopatias no Rio de Janeiro, Brasil. Revista Panamericana De Salud Pública = Pan American Journal of Public Health, 13, 154-159.
17. Lori, F., Foli, A., Groff, A., Lova, L., Whitman, L., Bakare, N., Pollard, R.B. & Lisziewicz, J. (2005) Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS, 19, 1173-1181.
18. Makani, J., Cox, S.E., Soka, D., Komba, A.N., Oruo, J., Mwamtemi, H., Magesa, P., Rwezaula, S., Meda, E., Mgaya, J., Lowe, B., Muturi, D., Roberts, D.J., Williams, T.N., Pallangyo, K., Kitundu, J., Fegan, G., Kirkham, F.J., Marsh, K. & Newton, C.R. (2011) Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS ONE, 6, e14699.
19. Maluf, S., Pra, D., Friedrisch, J.R., Bittar, C., da Silva, M.A., Henriques, J.A. & Silla, L. (2009) Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea. Environmental Toxicology and Pharmacology, 27, 26-29.
20. McGann, P.T., Flanagan, J.M., Howard, T.A., Dertinger, S.D., He, J., Kulharya, A.S., Thompson, B.W., Ware, R.E. & for the BABY-HUG Investigators, (2011a) Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG phase III clinical trial. Pediatric Blood & Cancer, 59, 254-257.
21. McGann, P.T., Howard, T.A., Flanagan, J.M., Lahti, J.M. & Ware, R.E. (2011b) Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. British Journal of Haematology, 154, 134-140.
22. Modell, B. & Darlison, M. (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, 86, 480-487.
23. Morrissey, L.K., Shea, J.O., Kalish, L.A., Weiner, D.L., Branowicki, P. & Heeney, M.M. (2009) Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatric Blood & Cancer, 52, 369-372.
24. Nichols, F.T., Jones, A.M. & Adams, R.J. (2001) Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. Journal of Neuroimaging, 11, 354-362.
25. Nozaki, A., Numata, K., Morimoto, M., Kondo, M., Sugimori, K., Morita, S., Miyajima, E., Ikeda, M., Kato, N., Maeda, S. & Tanaka, K. (2010) Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients. Antiviral Therapy, 15, 1179-1183.
26. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
27. Powars, D.R., Chan, L.S., Hiti, A., Ramicone, E. & Johnson, C. (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore), 84, 363-376.
28. Quinn, C.T., Rogers, Z.R., McCavit, T.L. & Buchanan, G.R. (2010) Improved survival of children and adolescents with sickle cell disease. Blood, 115, 3447-3452.
29. Ramakrishnan, M., Moisi, J.C., Klugman, K.P., Iglesias, J.M., Grant, L.R., Mpoudi-Etame, M. & Levine, O.S. (2010) Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. The Lancet Infectious Diseases, 10, 329-337.
30. Raphael, J.L., Kamdar, A., Beavers, M.B., Mahoney, D.H. & Mueller, B.U. (2008) Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatric Blood & Cancer, 51, 82-85.
31. Schneider, R.G., Ueda, S., Alperin, J.B., Levin, W.C., Jones, R.T. & Brimhall, B. (1968) Hemoglobin D Los Angeles in two Caucasian families: hemoglobin SD disease and hemoglobin D thalassemia. Blood, 32, 250-259.
32. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA, 289, 1645-1651.
33. Steinberg, M.H., McCarthy, W.F., Castro, O., Ballas, S.K., Armstrong, F.D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L. & Waclawiw, M.A. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology, 85, 403-408.
34. Tarone, R.E. & Ware, J. (1977) On Distribution-Free Tests for Equality of Survival Distributions. Biometrika, 64, 156-160.
35. Thornburg, C.D., Files, B.A., Luo, Z., Miller, S.T., Kalpatthi, R., Iyer, R., Seaman, P., Lebensburger, J., Alvarez, O., Thompson, B., Ware, R.E. & Wang, W.C. (2012) Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 120, 4310.
36. Vichinsky, E.P. (1991) Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Seminars in Hematology, 28, 220-226.
37. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
38. Wang, W.C., Langston, J.W., Steen, R.G., Wynn, L.W., Mulhern, R.K., Wilimas, J.A., Kim, F.M. & Figueroa, R.E. (1998) Abnormalities of the central nervous system in very young children with sickle cell anemia. Journal of Pediatrics, 132, 994-998.
39. Wang, W.C., Ware, R.E., Miller, S.T., Iyer, R.V., Casella, J.F., Minniti, C.P., Rana, S., Thornburg, C.D., Rogers, Z.R., Kalpatthi, R.V., Barredo, J.C., Brown, R.C., Sarnaik, S.A., Howard, T.H., Wynn, L.W., Kutlar, A., Armstrong, F.D., Files, B.A., Goldsmith, J.C., Waclawiw, M.A., Huang, X. & Thompson, B.W. (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, 377, 1663-1672.
40. Williams, T.N., Uyoga, S., Macharia, A., Ndila, C., McAuley, C.F., Opi, D.H., Mwarumba, S., Makani, J., Komba, A., Ndiritu, M.N., Sharif, S.K., Marsh, K., Berkley, J.A. & Scott, J.A. (2009) Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet, 374, 1364-1370.